# PAM Theragnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pam-theragnostics

- Industry: Medical Devices & Equipment
- Headquarters: Berlin, Germany
- Website: www.pam-t.com
- Total disclosed funding: $1.7M
- Latest round: Series A (Nov 24, 2021)
- Investors on record: 1

## About

Based in Berlin, Germany, and founded in 2020 by Dr. Andreas Bergmann, PAM Theragnostics GmbH is a research-based company engaged in the development of therapeutic and diagnostic approaches for diseases related to the maturation of the body's amidated peptide hormones. In January 2022, the company raised EUR 1.5 million in series A funding led by the investor Brandenburg Kapital. PAM Theragnostics was valued at EUR 6.88 million post-money after this funding round.

PAM Theragnostic's team of R&D scientists researches the human body's PAM enzyme and its role in detecting Alzheimer's Disease in patients.

As of 2022, the company plans to use its funding to advance and complete the preclinical development of the body's own PAM enzyme (peptidyl-glycine alpha-amidating monooxygenase). PAM Theragnostics intends to use its research on the PAM enzyme to develop tools for the early diagnosis of Alzheimer's Disease and develop a therapy for Alzheimer's patients.

## Funding rounds

- Series A, Nov 24, 2021, $1.7M — Brandenburg Kapital

## Investors

- Brandenburg Kapital (https://capitalatlas.ai/funds/brandenburg-kapital) — Series A